ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
-ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile -Four of six evaluable CLL patients, all with the BTK-C481S…